Robert J. Bitterman - 11 Sep 2025 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)

Role
Chairman, Pres. & CEO, Director
Signature
/s/ Lisa C. Carson, Attorney-in-fact
Issuer symbol
PHIO
Transactions as of
11 Sep 2025
Transactions value $
-$9,538
Form type
4
Filing time
15 Sep 2025, 08:28:05 UTC
Previous filing
11 Jun 2025
Next filing
19 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bitterman Robert J Chairman, Pres. & CEO, Director C/O PHIO PHARMACEUTICALS CORP., 411 SWEDELAND RD., STE 23-1080, KING OF PRUSSIA /s/ Lisa C. Carson, Attorney-in-fact 15 Sep 2025 0001304395

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHIO Common Stock, $.0001 par value Tax liability -$9.54K -4.11K -16.1% $2.32 21.4K 11 Sep 2025 Direct F1
transaction PHIO Common Stock, $.0001 par value Award $0 +250K +1167.08% $0.00 271K 11 Sep 2025 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold.
F2 Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
F3 Includes shares of common stock underlying unvested restricted stock units.

Remarks:

Exhibit 24 - Power of Attorney